Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07108036 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess Anktiva in Patients With Long Covid-19.

Study acronym: INTERRUPT_LC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv4
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 2025 to Nov 14, 2025 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Oct 2025 to Nov 14, 2025
    • Site details revised
  3. Start date: Aug 2025 to Oct 2025 Primary and study completion dates: Aug 2026 to Oct 2026v2 Show 1 more changeShow less
    • Primary and study completion dates: Aug 2026 to Oct 2026
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
Trial Details
NCT Number NCT07108036
Lead Sponsor ImmunityBio, Inc.
Conditions Long COVID
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov